Handong Dan, Dongdong Wang, Zixu Huang, Yizong Liu, Huiming Hou, Yujia Jin, Zongming Song
{"title":"玻璃体切除术加硅油与全氟丙烷填塞治疗近视性中央凹裂并中央凹脱离的疗效比较。","authors":"Handong Dan, Dongdong Wang, Zixu Huang, Yizong Liu, Huiming Hou, Yujia Jin, Zongming Song","doi":"10.3389/fmed.2025.1602386","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Vitrectomy with silicone oil or perfluoropropane (C3F8) tamponade is a standard of treatment for myopic foveoschisis with foveal detachment (MFFD). In this study, we compared the pre- and postoperative best-corrected visual acuity (BCVA) and maximum foveal thickness (MaxFT) of patients with MFFD who underwent vitrectomy with silicone oil or C3F8 tamponade.</p><p><strong>Methods: </strong>All patients underwent comprehensive ophthalmological examinations, including measurement of BCVA, axial measurement, optometry, intraocular pressure, slit-lamp examination, fundus examination, and optical coherence tomography. Patients with MFFD were divided into two groups. All patients underwent with 23-gauge pars plana vitrectomy with fovea-sparing internal limiting membrane peeling, and fluid-air exchange. One group underwent tamponade with silicone oil, whereas the other group underwent tamponade with C3F8. The silicone oil was completely removed upon complete resolution of MFFD. Phacoemulsification with intraocular lens implantation was performed when a lens opacity was noted during vitrectomy or along with silicone oil removal. BCVA and MaxFT were assessed at 1, 3, 6, and 12-months post-operatively. Patients with silicone oil were additionally assessed 3-months after silicone oil removal. All data were calculated using GraphPad Prism.</p><p><strong>Results: </strong>Forty-one patients with 41 eyes were enrolled in the study. Eighteen eyes were included in the silicone oil group, whereas 23 eyes were included in the C3F8 group. Both groups demonstrated significant improvement in BCVA and MaxFT at 1, 3, 6, and 12-months post-operatively. There was no significant difference in BCVA and MaxFT between both groups post-operatively. Transient ocular hypertension was noted in six and three cases in the silicone oil and C3F8 groups, respectively. One case in the C3F8 group developed a macular hole. There were no other complications in the two groups.</p><p><strong>Conclusion: </strong>Vitrectomy with fovea-sparing internal limiting membrane peeling, and silicone oil or C3F8 tamponade are effective and practical treatment options for MFFD.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1602386"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12500636/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparison of the effectiveness of vitrectomy with silicone oil or perfluoropropane tamponade for myopic foveoschisis with foveal detachment.\",\"authors\":\"Handong Dan, Dongdong Wang, Zixu Huang, Yizong Liu, Huiming Hou, Yujia Jin, Zongming Song\",\"doi\":\"10.3389/fmed.2025.1602386\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Vitrectomy with silicone oil or perfluoropropane (C3F8) tamponade is a standard of treatment for myopic foveoschisis with foveal detachment (MFFD). In this study, we compared the pre- and postoperative best-corrected visual acuity (BCVA) and maximum foveal thickness (MaxFT) of patients with MFFD who underwent vitrectomy with silicone oil or C3F8 tamponade.</p><p><strong>Methods: </strong>All patients underwent comprehensive ophthalmological examinations, including measurement of BCVA, axial measurement, optometry, intraocular pressure, slit-lamp examination, fundus examination, and optical coherence tomography. Patients with MFFD were divided into two groups. All patients underwent with 23-gauge pars plana vitrectomy with fovea-sparing internal limiting membrane peeling, and fluid-air exchange. One group underwent tamponade with silicone oil, whereas the other group underwent tamponade with C3F8. The silicone oil was completely removed upon complete resolution of MFFD. Phacoemulsification with intraocular lens implantation was performed when a lens opacity was noted during vitrectomy or along with silicone oil removal. BCVA and MaxFT were assessed at 1, 3, 6, and 12-months post-operatively. Patients with silicone oil were additionally assessed 3-months after silicone oil removal. All data were calculated using GraphPad Prism.</p><p><strong>Results: </strong>Forty-one patients with 41 eyes were enrolled in the study. Eighteen eyes were included in the silicone oil group, whereas 23 eyes were included in the C3F8 group. Both groups demonstrated significant improvement in BCVA and MaxFT at 1, 3, 6, and 12-months post-operatively. There was no significant difference in BCVA and MaxFT between both groups post-operatively. Transient ocular hypertension was noted in six and three cases in the silicone oil and C3F8 groups, respectively. One case in the C3F8 group developed a macular hole. There were no other complications in the two groups.</p><p><strong>Conclusion: </strong>Vitrectomy with fovea-sparing internal limiting membrane peeling, and silicone oil or C3F8 tamponade are effective and practical treatment options for MFFD.</p>\",\"PeriodicalId\":12488,\"journal\":{\"name\":\"Frontiers in Medicine\",\"volume\":\"12 \",\"pages\":\"1602386\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12500636/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fmed.2025.1602386\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1602386","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Comparison of the effectiveness of vitrectomy with silicone oil or perfluoropropane tamponade for myopic foveoschisis with foveal detachment.
Introduction: Vitrectomy with silicone oil or perfluoropropane (C3F8) tamponade is a standard of treatment for myopic foveoschisis with foveal detachment (MFFD). In this study, we compared the pre- and postoperative best-corrected visual acuity (BCVA) and maximum foveal thickness (MaxFT) of patients with MFFD who underwent vitrectomy with silicone oil or C3F8 tamponade.
Methods: All patients underwent comprehensive ophthalmological examinations, including measurement of BCVA, axial measurement, optometry, intraocular pressure, slit-lamp examination, fundus examination, and optical coherence tomography. Patients with MFFD were divided into two groups. All patients underwent with 23-gauge pars plana vitrectomy with fovea-sparing internal limiting membrane peeling, and fluid-air exchange. One group underwent tamponade with silicone oil, whereas the other group underwent tamponade with C3F8. The silicone oil was completely removed upon complete resolution of MFFD. Phacoemulsification with intraocular lens implantation was performed when a lens opacity was noted during vitrectomy or along with silicone oil removal. BCVA and MaxFT were assessed at 1, 3, 6, and 12-months post-operatively. Patients with silicone oil were additionally assessed 3-months after silicone oil removal. All data were calculated using GraphPad Prism.
Results: Forty-one patients with 41 eyes were enrolled in the study. Eighteen eyes were included in the silicone oil group, whereas 23 eyes were included in the C3F8 group. Both groups demonstrated significant improvement in BCVA and MaxFT at 1, 3, 6, and 12-months post-operatively. There was no significant difference in BCVA and MaxFT between both groups post-operatively. Transient ocular hypertension was noted in six and three cases in the silicone oil and C3F8 groups, respectively. One case in the C3F8 group developed a macular hole. There were no other complications in the two groups.
Conclusion: Vitrectomy with fovea-sparing internal limiting membrane peeling, and silicone oil or C3F8 tamponade are effective and practical treatment options for MFFD.
期刊介绍:
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world